ArticleCurrent microbiology2025
Biochanin A Suppresses Growth and Biofilm Formation of Fluconazole-Resistant Candida auris.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biochanin A, a Plant Isoflavone, Disrupts Peptidoglycan Biosynthesis by DownregulatingAntibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Invasive fungal infections, especially from Candida auris (C. auris), are a serious threat to immunocompromised patients because of multidrug resistance. Therefore, research into novel antifungal agents or adjuvants for pre-existing treatments is necessary. This study examined the therapeutic potential of biochanin A as an antifungal and anti-biofilm agent against fluconazole-resistant C. auris (FRCA). Its efficacy was determined through minimum inhibitory concentration (MIC), minimum biofilm inhibitory concentration (MBIC), and minimum biofilm eradication concentration (MBEC) assays. The fungal metabolic activity in biofilms was measured using the XTT reduction assay and the results were visualized by confocal laser scanning microscopy (CLSM). We also evaluated the effect of biochanin A on C. auris adhesion and the expression of resistance and virulence-associated genes. Biochanin A inhibited the growth of several C. auris strains, with MIC₉₀ values ranging from 16 to 64 µg/mL, as well as a dose-dependent reduction in MBIC and MBEC. The XTT assay and CLSM confirmed a significant inhibition of metabolic activity and viability. In addition, biochanin A reduced C. auris adherence to epithelial cells and downregulated the expression of the azole resistance gene ERG11 and the extracellular matrix gene KRE6. The results suggest that biochanin A is an effective alternative for managing fluconazole-resistant C. auris infections.
Indexed as
Identifiers
41171348What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.